Non-consensual abortion drug crime

Summary#

The bill creates a new federal crime for knowingly and intentionally giving a pregnant woman an abortion-inducing drug without her informed consent when the drug is in or affects interstate or foreign commerce. It allows criminal penalties (fines and up to 25 years in prison), extra penalties if the woman suffers serious bodily injury or dies, and a private civil right of action with money damages and attorney’s fees. The bill also expands the chapter title from “Partial-birth abortions” to “Abortions.”

  • Main change: Adds a federal offense for non-consensual administration of abortion-inducing drugs (includes mifepristone and misoprostol).
  • Criminal penalties: Up to 25 years in prison and fines; attempts and conspiracies carry the same penalties.
  • Enhanced penalty: Additional up to 25 years if the act causes serious bodily injury or death.
  • Civil remedy: Victims may sue for verifiable damages, statutory damages equal to three times the cost of injuries, punitive damages, and attorney’s fees; defendants can recover fees if the suit is found frivolous.
  • Definitions: “Informed consent,” “abortion-inducing drug,” and what counts as conspiring are defined in the bill.

What it means for you#

  • Women who were given abortion drugs without consent: The bill would allow you to bring a federal civil lawsuit for damages and to seek criminal enforcement by the government.
  • Health care providers and people who administer drugs: If you knowingly and intentionally give an abortion-inducing drug without a woman’s informed consent, you could face federal criminal charges and civil suits.
  • Pharmacies, mailers, and sellers of abortion drugs: The bill says “conspires to commit an offense” can include selling or mailing a drug without taking reasonable measures to ensure the requester is a pregnant woman wishing to obtain an abortion. This could expose sellers to criminal or civil liability if they do not take steps described in the bill.
  • Patients seeking abortion drugs: The bill requires that a woman give “informed consent” (a voluntary, knowing agreement after full information about nature, purpose, risks, and consequences) before an abortion-inducing drug can be administered without legal risk to the administrator.
  • Courts and lawyers: The bill creates a new category of federal criminal cases and civil litigation. Plaintiffs can recover triple statutory damages plus punitive damages and attorney’s fees; defendants can recover fees if the suit is frivolous.
  • General public / interstate commerce: The federal rule applies only when the conduct is “in or affecting interstate or foreign commerce,” which could bring many cases involving drugs shipped across state lines under federal law. This could mean federal jurisdiction in many situations where drugs cross state borders.

Expenses#

No plain-language federal cost estimate or fiscal note is included in the provided material.

  • No publicly available information about federal budget effects is included in the bill text supplied.
  • Likely fiscal effects (inferred): this could increase federal law enforcement, prosecution, and federal court costs; it could also generate civil litigation costs and monetary awards paid by defendants. Exact amounts are not provided.

Proponents' View#

The bill appears intended to protect women from being given abortion-inducing drugs without their voluntary, informed agreement. Possible arguments in favor, based on the bill text, include:

  • The bill appears intended to deter and punish the non-consensual administration of drugs meant to cause abortions.
  • It creates both criminal penalties and a civil path for victims to receive compensation for physical and psychological injuries.
  • By naming common drugs (mifepristone and misoprostol), the bill targets acts involving medicines currently used for medical abortion.
  • Expanding the chapter heading to “Abortions” suggests a broader federal focus on non-consensual conduct involving abortion drugs.

Opponents' View#

The bill’s text raises several questions and potential concerns that someone might reasonably raise:

  • The bill does not give a fiscal estimate, so the federal cost for investigations, prosecutions, and courts is unclear.
  • Terms such as “reasonable measures” (to verify a requester) and how to prove “informed consent” are not fully detailed. This could create uncertainty for pharmacies, telehealth providers, and clinicians.
  • The interstate-commerce trigger could make many routine distribution actions federal offenses when drugs cross state lines. This could expand federal reach into areas usually handled by states.
  • The civil damages scheme (triple damages, punitive damages, and fee awards) may increase litigation and could impose large financial liabilities on providers, pharmacies, or others.
  • The bill does not clearly state exceptions for emergency medical situations, incapacitated patients, or minors; it is unclear how it would apply in those circumstances.
  • Cumulative criminal penalties (additional prison time for injury or death) may produce very severe sentences; the text does not explain how sentences would be coordinated with state charges on the same conduct.